Lonza uses its ‘global footprint’ in hematopoietic commercialization agreement

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/carloscastilla)
(Image: Getty/carloscastilla)

Related tags: Lonza, Stem cell, Research, In vitro, Personalized medicine, Commercialization

Lonza enters private label partnership to manufacture and globally commercialize AllCell’s hematopoietic primary cells to provide greater access to researchers.

Lonza and AllCells are both manufacturers of hematopoietic stem cells, with Lonza producing them at facilities in North Carolina, while AllCell has facilities in California.

A Lonza spokesperson told us, that per this agreement, cells from both manufacturers will now be offered through Lonza’s portfolio and will bear Lonza branding “significantly expanding the range of products available to researchers.”

“By working together, we are able to bring a larger range of products to a broader worldwide customer base. Lonza’s global footprint expands access to customers around the globe, while AllCells portfolio fills some key gaps in Lonza’s existing [hemato]Poietics cell offering,”​ the Lonza spokesperson added.

Scientists will now be able to access this expanded portfolio of hematopoietic cells to further research in drug discovery, toxicity testing, cell therapy, and personalized medicines beyond North American borders.

In a statement, Don Klabunde, CEO, AllCells, explained, “By leveraging our customization expertise, speed and flexibility to manufacture hematopoietic cells of superior viability and quality, and with Lonza's extensive reach, we will improve the availability of highly purified cells from different tissue sources to enhance a variety of research needs.”​ 

Hematopoietic primary cells are often used in in vitro research because the cells reflect in vivo​ morphology, metabolism, and growth characteristics. Researchers have expressed that obtaining these cells often requires finding multiple donors and performing a series of cell isolations. 

Related news

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

QPS: Global Custom-Built Research Services

QPS: Global Custom-Built Research Services

QPS | 16-Dec-2019 | Product Brochure

Performing complex studies in special populations with remarkable agility. Clinical research just got better with QPS’ Custom-Built Research Services....

Related suppliers

Follow us


View more